Clinical Trials Logo

Filter by:
NCT ID: NCT00089583 Completed - Clinical trials for Infection, Human Immunodeficiency Virus I

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

Start date: July 2004
Phase: Phase 2
Study type: Interventional

This is a 48-week study to collect information on the safety and activity of an investigational medicine in patients, ages 2 to 18 years old, with HIV infection .

NCT ID: NCT00088530 Completed - Clinical trials for Lymphoma, Non-Hodgkin

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Start date: July 2004
Phase: Phase 3
Study type: Interventional

BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models. This cytotoxic agent has structural similarities with mitoxantrone as well as general similarities with anthracyclines (such as the tricyclic central quinoid chromophore).

NCT ID: NCT00088478 Completed - Schizophrenia Clinical Trials

Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia

Start date: June 2004
Phase: Phase 3
Study type: Interventional

Key objectives of this clinical study are to: - Determine how well intramuscular (IM) olanzapine depot works compared to placebo - Evaluate the safety and tolerability of IM olanzapine depot compared to placebo - Evaluate different doses of IM olanzapine depot compared to placebo to identify the best dose(s).

NCT ID: NCT00088465 Completed - Clinical trials for Schizoaffective Disorder

Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

Start date: August 2004
Phase: Phase 3
Study type: Interventional

This is a long-term, open-label clinical study designed to enable longer-term treatment of patients completing other clinical studies with intramuscular olanzapine depot. Key objectives of the study are to: - Determine how well intramuscular (IM) olanzapine depot works during long-term treatment, - Evaluate the safety and tolerability of IM olanzapine depot during long-term treatment, - Determine the blood levels of IM olanzapine depot in patients during long-term treatment

NCT ID: NCT00087490 Completed - Clinical trials for Methicillin Resistant Staphylococcus Aureus (MRSA)

Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

Start date: October 2004
Phase: Phase 4
Study type: Interventional

To determine if linezolid is superior to vancomycin in the treatment of complicated skin and soft tissue infections due to MRSA in adult subjects

NCT ID: NCT00086580 Completed - Clinical trials for B-Cell Chronic Lymphocytic Leukemia

Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients

Start date: July 2004
Phase: Phase 3
Study type: Interventional

This is a Phase 3, prospective, multicenter, open-label, randomized, controlled study to evaluate and compare the efficacy and safety of fludarabine plus alemtuzumab versus fludarabine alone as second-line therapy for patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL). Patients who meet all eligibility criteria and sign the informed consent document may be entered on the study.

NCT ID: NCT00084266 Completed - Clinical trials for Methicillin Resistant Staphylococcus Aureus (MRSA)

Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

ZEPHYR
Start date: October 2004
Phase: Phase 4
Study type: Interventional

To determine if linezolid is superior to vancomycin in the treatment of nosocomial (acquired in the hospital) pneumonia due to Methicillin Resistant Staphylococcus Aureus (MRSA) in adult subjects. Subjects entered in to the study will have proven healthcare-associated methicillin-resistant Staphylococcus aureus pneumonia which will be treated with either linezolid or vancomycin.

NCT ID: NCT00083889 Completed - Clinical trials for Carcinoma, Renal Cell

SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma

Start date: August 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).

NCT ID: NCT00082433 Completed - Breast Cancer Clinical Trials

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Start date: November 2003
Phase: Phase 3
Study type: Interventional

The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine (Xeloda) provides measurable clinical benefits over capecitabine alone in women with metastatic breast cancer. Patients should have previously received an anthracycline and a taxane. The safety of this treatment will also be studied.

NCT ID: NCT00082407 Completed - Clinical trials for Diabetes Mellitus, Type 2

Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin

Start date: November 2003
Phase: Phase 3
Study type: Interventional

This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c).